Shanghai, September 21, 2020 – 3D Medicines Inc., a clinical stage biopharmaceutical company focusing on the development and commercialization of differentiated immuno-oncology drugs, and GenScript ProBio, a leading CDMO (contract development and manufacturing organization) in China with one-stop antibody drugs R&D solutions, announced a collaboration agreement on stages including pre-clinical discovery and pharmacological research of biological macromolecule drug projects.

By combining the advantages, 3D Medicines and GenScript ProBio will devote to the R&D of Class I novel biological drugs with independent intellectual property rights, development of production technologies, registration at NMPA (National Medical Products Administration) and FDA (Food and Drug Administration) and commercialization, thus achieving a win-win collaboration on drug R&D and jointly pushing forward the rapid development of antibody drugs in China. In the coming years, 3D Medicines will establish an in-depth collaboration on several projects on monoclonal/bispecific antibody drugs with GenScript ProBio.

John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines (Third on the Right)

Dr. Brian Min, CEO of GenScript ProBio (Third on the Left)

Signed the Collaboration Agreement as Representatives 

“We are pleased to establish the collaboration with GenScript ProBio, which provides continuous support for our product portfolio in the field of immuno-oncology drugs,” John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines commented, “3D Medicines focuses on the development of differentiated immuno-oncology drugs. Through the in-depth collaboration, we believe that we will utilize the advanced antibody drug R&D platform and rich experience of GenScript ProBio, combine our advantages and continue to actively expand our product pipeline of innovative antibody drugs, striving to realize our vision of helping cancer patients to live with prolonged survival time and a better quality of life sooner.”

Dr. Brian Min, CEO of GenScript ProBio, commented, “’Innovation through Collaboration’ is the mission of GenScript ProBio, and helping 3D Medicines to expand the product pipeline of innovative antibody drugs, as well as supporting the R&D and commercialization of their immuno-oncology drugs is another step towards our goal. By establishing the collaboration, we believe that we will actively explore and arrange the R&D of differentiated immuno-oncology drugs with our partner, make use of our rich experience and convenient production processes, provide more patients with better treatment solutions that benefit the patients worldwide, with the help of 3D Medicines, a biopharmaceutical company with rich experience in innovative drug R&D. We look forward to continuing our collaboration with 3D Medicines to provide continuous support for immuno-oncology drugs.”

About 3D Medicines Inc.

3D Medicines, Inc. is a biopharmaceutical company at the stage of late clinical development and early commercialization. Taking “help people with cancer live longer and better” as our concept, 3D Medicines aims at the future long-term survival of cancer patients and focuses on the development of differentiated immuno-oncology drugs, helping cancer patients to live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both innovative biological and small-molecule anti-cancer drugs, as well as a professional team capable of global development, registration and commercialization operation for new drugs.

About GenScript ProBio

GeneScript ProBio, a leading CDMO (contract development and manufacturing organization) in China with one-stop antibody drugs R&D solutions, is dedicated to providing end-to-end service from target to commercialization.

GenScript ProBio's one-stop antibody drug development solutions include antibody drug discovery (hybridoma, phage display, single B cell, fully human and bispecific antibody technologies), antibody engineering (antibody humanization, affinity maturation, developability assessment and optimization) and antibody evaluation (bioactivity and physiochemical characteristics). As for pre-clinical development, GenScript ProBio provides customers with integrated platform and service from stable cell line generation to process development, providing high-quality materials for IND and clinical trials and accelerating the development process. GenScript ProBio's integrated GCT solution covers IND preparation as well as clinical sample and commercial production. Process development quality systems ensure compliance, data integrity and traceability, and all test deviations are strictly studied and documented.

Toward the mission of “Innovation through Collaboration”, GenScript ProBio is committed to helping customers to shorten the timeline for biological drugs from development to clinical use, significantly cutting down the R&D costs, accelerating the commercialization of medicines, and building a healthy future while making contributions to the realization of “Made in China” in the pharmaceutical industry by 2025.

For more information, please visit：https://www.genscriptprobio.cn